Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2026.1783059 Correction Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy BarrónFeliciano 1 Conceptualization Data curation Formal analysis Investigation Methodology Writing – original draft Writing – review & editing SánchezRoberto 1 Conceptualization Data curation Formal analysis Writing – original draft Writing – review & editing Arroyo-HernándezMarisol 1 Data curation Formal analysis Investigation Writing – original draft Writing – review & editing BlancoCarolina 2 Data curation Formal analysis Investigation Writing – original draft Zatarain-BarrónZyanya L. 1 Data curation Formal analysis Investigation Writing – original draft CatalánRodrigo 1 Data curation Formal analysis Investigation Writing – review & editing Ramos-RamírezMaritza 1 Data curation Formal analysis Investigation Writing – review & editing CardonaAndrés F. 3 4 5 Conceptualization Data curation Formal analysis Investigation Methodology Writing – review & editing Flores-EstradaDiana 1 Data curation Investigation Writing – original draft ArrietaOscar 1 * Conceptualization Formal analysis Methodology Supervision Writing – original draft Writing – review & editing Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico Cancer Center, ABC Medical Center, México City, Mexico Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia Correspondence: Oscar Arrieta, ogar@unam.mx 06 02 2026 2026 16 1783059 07 01 2026 19 01 2026 Copyright © 2026 Barrón, Sánchez, Arroyo-Hernández, Blanco, Zatarain-Barrón, Catalán, Ramos-Ramírez, Cardona, Flores-Estrada and Arrieta. 2026 Barrón, Sánchez, Arroyo-Hernández, Blanco, Zatarain-Barrón, Catalán, Ramos-Ramírez, Cardona, Flores-Estrada and Arrieta https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy By Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, Ramos-Ramírez M, Cardona AF, Flores-Estrada D and Arrieta O (2020) Front. Oncol. 10:570233. doi: 10.3389/fonc.2020.570233 checkpoint immune therapy pneumonitis radiotherapy NSCLC lung cancer immune related adverse effects section-at-acceptance Thoracic Oncology

In the published article, the “No. (Events)” values for the “Wood-smoke exposure” row and Pneumonitis rows in Table 3 were transcribed incorrectly during table formatting. The Cox analysis for wood-smoke exposure and both pneumonitis categories (any grade and ≥2) were performed with the correct underlying data; only the “No. (Events)” figures in that row are misprinted.

Factors associated with overall survival.

Unadjusted Adjusted
No. (Events) Median (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Overall 95(42) 16.29 (10.8-21.7)          
Sex
Female 55(20) 19.6(15.3-23.9)          
Male 40(22) 12.4(10.6-21.4) 0.18 0.66 (0.36-1.22) 0.18 1.56 (0.34-1.18) 0.15
Age (years)
<60 42(21) 16.2(10.6-21.9)          
≥60 53(21) 19.6(5.3-33.9) 0.62 0.85 (0.46-1.57) 0.62 0.81 (0.44-1.50) 0.51
Histology
Adenocarcinoma 81 (35) 16.3 (12.9-19.7)
Other 14 (7) 7.3 (NA-NA) 0.64 1.21 (0.53-2.74) 0.64
Tobacco exposure
No 46(19) 16.2(10.0-22.5)        
Yes 49(23) 17.0(5.5-28.5) 0.72 0.94 (0.69-1.28) 0.72  
Wood-smoke exposure
No 72(33) 16.1(11.1-21.1)        
Yes 23(29) 19.9(2.68-36) 0.46 0.75 (0.36-1.59) 0.45  
ECOG PS
<2 92(39) 17.0(10.9-23.1)        
≥2 3(3) 16.1(2.01-30.30) 0.67 1.11 (0.47-2.64) 0.80  
CNS Metastases
No 65 (29) 16.2 (10-7-21.6)
Yes 30 (13) 18.2 (10.9-21.7) 0.99 0.99 (.52-1.92) 0.98
EGFR mutation
Absent (wild-type) 71(29) 17.0 (13.2-20.8)          
Present (EGFR mutated) 15(8) 12.4 (5.8-1.2) 0.21 1.24 (0.18-1.89) 0.3    
Radiotherapy
Yes 40(19) 17.5(10.4-23.7)        
No 55(23) 16.2(8.4-24.0) 0.930 0.97 (0.52-1.80) 0.93    
Pneumonitis
No 73(31) 16.2(9.5-23.0)        
Yes 22(11) 16.1(10.3-22.0) 0.71 1.13 (0.57-2.26) 0.71  
Pneumonitis >2
No 83(33) 22.3(14.3-30.41)    
Yes 12(9) 7.5(0.51-14.5)  0.048 2.48 (1.18-5.23) 0.028  2.54 (1.20-5.34) 0.014 

Bold text indicate analyzed characteristics and corresponding p values.

The corrected table appears below.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland